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The simultaneous dysfunction of two enzymes within the heme biosynthetic pathway in a single patient is rare.
Not more than 15 cases have been reported. A woman with a transient episode of severe photosensitivity
showed a biochemical porphyrin profile suggestive of hereditary coproporphyria (HCP), whereas some of
her relatives had a profile that was suggestive of variegate porphyria (VP). HCP and VP result from a partial
enzymatic deficiency of coproporphyrinogen oxidase (CPOX) and protoporphyrinogen oxidase (PPOX),
respectively. DNA analysis in the index patient revealed mutations in both the CPOX and PPOX genes,
designated as c.557-15C4G and c.1289dupT, respectively. The CPOX mutation leads to a cryptic splice site
resulting in retention of 14 nucleotides from intron 1 in the mRNA transcript. Both mutations encode null alleles
and were associated with nonsense-mediated mRNA decay. Given the digenic inheritance of these null
mutations, coupled with the fact that both HCP and VP can manifest with life-threatening acute neurovisceral
attacks, the unusual aspect of this case is a relatively mild clinical phenotype restricted to dermal
photosensitivity.
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INTRODUCTION
Hereditary coproporphyria (HCP; OMIM 121300) and variegate
porphyria (VP; OMIM 176200) are rare autosomal dominantly
inherited disorders. Individuals with either HCP or VP may
develop photosensitivity, acute neurovisceral attacks, or both
(Puy et al., 2010). HCP results from a partial catalytic deficiency
of coproporphyrinogen oxidase (CPOX; E.C. 1.3.3.3) and VP
from partial deficiency of protoporphyrinogen oxidase (PPOX;
E.C. 1.3.3.4), the sixth and seventh enzymes of heme
biosynthesis, located in the mitochondrium (Martasek, 1998;
Bickers and Frank, 2003; Sassa, 2006; Puy et al., 2010).
A decrease in activity of either of these enzymes may
lead to a pathological accumulation and measurable excre-
tion of porphyrins and/or porphyrin precursors in urine and
stool, and possibly to clinical symptoms. During an acute
porphyric attack, a broad spectrum of largely nonspecific
and distinct neurovisceral symptoms can manifest, including
severe colicky abdominal pain, nausea and vomiting,
hypertension, tachycardia, psychiatric symptoms, hemi-
and tetraplegia, respiratory failure, and coma (Puy et al.,
2010). Attacks may be provoked by several porphyrino-
genic factors, such as drugs, alcohol, hormonal changes,
infections, and dieting (Bickers and Frank, 2003). In addition
to neurovisceral findings, individuals with HCP and VP
can also present with cutaneous symptoms on sun-exposed
skin, including fragility, blistering, erosions, milia, scars,
and post-inflammatory hyperpigmentation (Puy et al.,
2010). Another cutaneous feature, facial hypertrichosis,
may be observed in VP but rarely in HCP (Bickers and Frank,
2003).
The diagnosis of HCP and VP can be established on the
basis of biochemical examination of plasma, urine, and stool
samples (Bickers and Frank, 2003). Sometimes, however,
these analyses may be inconclusive. This particularly holds
true in rare patients with a simultaneous deficiency of two
enzymes of heme biosynthesis, referred to as dual porphyria
(Poblete Gutierrez et al., 2006). Subsequent determination of
the residual enzymatic activity of both enzymes may be
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conclusive, but only DNA analysis is confirmative (Bickers
and Frank, 2003; Poblete Gutierrez et al., 2006).
In HCP, heterozygosity for mutations in the CPOX gene,
located on chromosome 3q11.2, results in aB50% reduction
in enzyme activity (Martasek, 1998; Sassa, 2006). Similarly,
heterozygosity for mutations in the PPOX gene, located on
chromosome 1q21–22, results in a 50% reduction in the
activity of the encoded enzyme. However, only about
15–20% of mutation carriers for either gene develop clinical
symptoms due to incomplete penetrance of the diseases, and
symptoms usually do not develop before puberty (Sassa,
2006).
Here, we describe a family in which some individuals
showed the biochemical characteristics of HCP, whereas the
biochemical abnormalities of others were suggestive of VP.
On the basis of additional enzyme activity measurements of
PPOX and CPOX in Epstein–Barr virus-transformed lympho-
blastoı¨d cell lines, together with additional molecular genetic
studies, we identified a woman in this family who carried
mutations in both the CPOX and the PPOX genes. In spite of
carrying mutations in two genes in the heme biosynthetic
pathway, the clinical phenotype was restricted to mild
dermal photosensitivity.
RESULTS
Biochemical and enzymatic tests
Biochemical examination of urine and feces in the index
patient (Figure 1a and individual II-5 in Figure 1b) repeatedly
showed an increased urinary excretion of uroporphyrin and
coproporphyrin and elevated levels of coproporphyrin and
protoporphyrin in the stool, with coproporphyrin concentra-
tions exceeding those of protoporphyrin (Table 1). Results of
plasma scanning, plasma aminolevulinic acid and porpho-
bilinogen levels, and CPOX and PPOX activities are also
included in Table 1.
Subsequently, several other family members were exam-
ined biochemically. Whereas some of these individuals had
increased coproporphyrin levels in the feces, another mainly
had increased levels of protoporphyrin (Table 1).
DNA analysis
In the index patient, we detected mutations in both the CPOX
and PPOX genes. The CPOX mutation is located in intron 1
and consists of a C-to-G transversion 15 bp upstream of the
splice-acceptor site, designated as c.557-15C4G (Figure 2a).
The PPOX mutation is located in exon 12 and consists of a
T-insertion at position 1290 of the PPOX complementary
DNA, designated c.1289dupT (Figure 2b). The results of DNA
analysis in the index patient and the family members tested
are depicted in Table 1 and Figure 1b.
Individuals with low PPOX levels carrying the PPOX gene
mutation were also found in descendants of two of the three
paternal great uncles (from two marriages) of the index
patient (data not shown).
Reverse transcription-PCR and quantitative real-time PCR
Reverse transcription-PCR showed that the c.557-15C4G
mutation creates a cryptic AG splice-acceptor signal that is
located 14 bp upstream of the usual splice-acceptor site of
intron 1 of the CPOX gene (Figure 2c and d).
At the RNA level, both mutation c.557-15C4G in the
CPOX gene and mutation c.1289dupT in the PPOX gene are
associated with mRNA decay of 78% and 64%, respectively,
compared with expression in a healthy unrelated control
(data not shown).
Not investigated
No mutation
VP mutation
HCP mutation
Index
1
I
II
III
IV
2
1 2 3 4 5
1 2 3 4 5 6
1 2 3 4 5
Figure 1. Dutch porphyria family studied. (a) Index patient with dual
porphyria: note the mild facial hypertrichosis. (b) Individuals marked with a
dark grey symbol were heterozygotes for the CPOX mutation, c.557-15C4G;
individuals marked with a black symbol were heterozygotes for the PPOX
mutation, c.1289dupT; individuals indicated with a white symbol were not
investigated; and individuals delineated in speckled grey did not carry a
mutation.
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DISCUSSION
An accurate diagnosis of the different types of porphyria can
usually be made through biochemical analyses of urine,
stool, erythrocytes, and plasma. These techniques, however,
may be insufficient in diagnosing rare patients with dual
porphyria (Akagi et al., 2006; Poblete Gutierrez et al., 2006).
The index patient (individual II-5 in Figure 1b) repeatedly
showed a biochemical profile suggesting HCP, with fecal
coproporphyrin concentrations higher than those of proto-
porphyrin. When we examined the patient in our outpatient
clinic, however, we noted mild facial hypertrichosis (Figure
1a). The cutaneous symptoms in HCP, including skin fragility,
vesiculae and bullae, and scarring and hyperpigmentation,
cannot be distinguished clinically from those encountered in
porphyria cutanea tarda and VP. Nevertheless, skin lesions
rarely occur as the only clinical manifestation in HCP and, to
the best of our knowledge, there have been no reports of a
patient with genetically confirmed HCP with facial hyper-
trichosis, nor have we seen one in our porphyria outpatient
clinic. Therefore, the latter clinical observation in the index
patient led to biochemical examination and DNA analysis of
the index patient and other family members.
Some family members (individuals I-2, II-1, and II-5 in
Figure 1b) had stool porphyrin profiles indicative of HCP,
whereas another (individual I-1 in Figure 1b) showed values
more compatible with VP (Table 1). The differentiation
between HCP and VP may be difficult, mainly because the
conditions can present with similar clinical manifestations
and overlapping biochemical profiles. In symptomatic
patients, plasma scanning can be of diagnostic help because
individuals with clinically overt VP usually have a character-
istic plasma emission peak at 624–626 nm (Poh-Fitzpatrick,
1980). However, this technique usually fails to identify
asymptomatic carriers or children with VP (Da Silva et al.,
1995). As enzymatic measurements indicated that some
family members might suffer from HCP, whereas others might
have VP, we decided to perform DNA analysis in both the
CPOX and PPOX genes in the index patient and eight
relatives.
The CPOX mutation we found was previously reported
in a distant member of this family (Rosipal et al., 1999).
We established that this mutation leads to a null allele
by introducing a premature termination codon resulting in
substantial mRNA decay (Figure 2c and d). The PPOX
mutation we detected has not been previously described
and also generates a null allele associated with mRNA decay.
Until now, 15 patients and families with simultaneous
deficiency of two enzymes along the heme biosynthetic
pathway have been reported, indicating that dual porphyrias
are rare or may be underdiagnosed (Poblete Gutierrez et al.,
2006). These results were based mainly on biochemical and
enzymatic studies, and only in two instances they were
confirmed by molecular genetic analysis (Akagi et al., 2006;
Harraway et al., 2006; Poblete Gutierrez et al., 2006). To our
knowledge, the constellation of digenic mutations in the
CPOX and PPOX genes has not yet been reported.
In light of the digenic inheritance pattern and the asso-
ciation of both mutations with nonsense-mediated mRNA
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decay, we wondered why our patient revealed only mild
cutaneous symptoms and had not experienced acute por-
phyric attacks, in particular, considering the fact that the
related patient with mutation c.557-15C4G in the CPOX
gene reported by Rosipal et al. (1999) did present with acute
clinical symptoms, comprising abdominal pain, nausea, and
vomiting. Considering the turnover rates of the two enzymes
involved, perhaps a more severe clinical phenotype might
have been expected as a consequence of the two null
alleles (Labbe et al., 1985). To the best of our knowledge, the
other family members in this pedigree had never experienced
overt clinical signs of photosensitivity. Interestingly, the
biochemical values of the index patient’s brother (individual
II-1), who is also heterozygous for mutations in both CPOX
and PPOX, were considerably lower than those found in his
sister (Table 1). This finding underlines the fact that in the
acute hepatic porphyrias, overt clinical disease is more
common in women, most likely due to the association with
hormonal status and ingestion of hormonal preparations
such as oral contraconceptives. Nevertheless, it should be
mentioned that this brother and the father of the index patient
were reported with a nonspecific thickening of the facial skin
and pronounced facial folds, which could reflect the long-
term consequence of previous mild symptoms of cutaneous
C T T A C C T A A/G T/G T T T T G/ G/ C
C T T A C C T A G T T T T T G C C
c.1,289dupT
C T T T T T T A C/G A T T T C T A T
C T T T T T T A C A T T T C T A T
c.557-15C>G
G A A G A T T T C T A T A C A C A G G A G G T
c.557-15C>G
Exon 1 Intron 1 Exon 2Intron 1
Exon 1 Exon 2
G G A A G G T A A G T T A C A T T T C T A T A C A C A G G A G G T
Figure 2. Molecular genetic analysis. (a) Mutation of c.557-15C4G in the coproporphyrinogen oxidase (CPOX) gene (lower panel, indicated by an arrow)
compared with the wild-type allele (top panel). (b) Mutation of c.1289dupT in the protoporphyrinogen oxidase gene (lower panel, indicated by an arrow)
compared with the wild-type allele (top panel). Note that the sequence is depicted in reverse orientation. (c) Exon 1–intron 1–exon 2 boundaries on the genomic
DNA level. (d) Cryptically spliced CPOX complementary DNA derived from the mutant allele (cloned from a reverse transcription-PCR product).
2252 Journal of Investigative Dermatology (2011), Volume 131
AM van Tuyll van Serooskerken et al.
Dual Porphyria
porphyria. By contrast, in the two patients with the other
genetically confirmed dual porphyrias, the clinical phenotype
was heterogeneous, with one patient experiencing only
cutaneous symptoms and the other showing signs of an
acute porphyric attack (Akagi et al., 2006; Harraway et al.,
2006). The heterogeneous clinical phenotypes observed in
our index patient and the two individuals with dual porphyria
support the current notion that there is little evidence for
genotype–phenotype correlations either in the common types
of porphyria, which can be inherited in an autosomal
dominant or recessive manner, or in the rare patients with
dual porphyrias. The notable exception to this rule is
autosomal recessive congenital erythropoietic porphyria, in
which a certain degree of genotype–phenotype correlation
has been described in those individuals carrying the C73R
allele (Warner et al., 1992).
In conclusion, we have identified a patient with, to our
knowledge, a previously unreported type of dual porphyria,
confirmed on the molecular genetic level. We strongly
believe that it is important to perform DNA analysis if a dual
porphyria is suspected, especially when the biochemical data
are not completely conclusive. Molecular genetic analysis for
the different types of porphyria is offered by several national
porphyria centers throughout Europe (for an overview see
http://www.porphyria-europe.com) and, in the United States,
by the Department of Human Genetics at The Mount Sinai
School of Medicine in New York, NY. Genetic analysis
permits an unequivocal diagnosis and also provides affected
individuals with the opportunity for genetic counseling. This
is an important issue, as an acute neurovisceral porphyric
attack can be life threatening.
MATERIALS AND METHODS
Subjects, medical history, and diagnosis
The index patient (individual II-5 in Figure 1b) was a 56-year-old Dutch
Caucasian woman who developed severe photosensitivity reactions in
her 20s, characterized by blisters, vesicles, and erosions on both hands,
the nose, and ears. She was using an oral contraconceptive drug
(norethindrone/ethinyl estradiol) and had experienced a cold in the
weeks preceding the skin symptoms. After cessation of the oral
contraceptive, her symptoms resolved within several weeks. Thereafter,
she never again experienced similar symptoms and her further medical
history was unremarkable. Her parents were non-consanguineous and
the family history was negative with regard to neurological, liver, or
kidney disease. When first seen in our clinic, mild facial hypertrichosis
was the only abnormal physical finding (Figure 1a).
Biochemical and enzymatic tests
Urine, fecal, and plasma porphyrin scanning was performed as
described previously (De Rooij et al., 2003). The use of different
eluting solvents and fluorescence scanning permits differentiation of
protoporphyrin, coproporphyrin, and uroporphyrin. Plasma amino-
levulinic acid and porphobilinogen were measured using enzymatic
conversion to uroporphyrin and fluorometric detection. Epstein–Barr-
transformed lymphoblastoid cell lines were prepared from peripheral
blood by standard methods. CPOX and PPOX activities were
measured in these cell lines as described in detail elsewhere
(De Rooij et al., 2003).
DNA analysis
After written informed consent was obtained according to guidelines
set forth by the local institutional review board and the Declaration
of Helsinki Principles, peripheral blood samples from the index
patient and eight family members were collected in tubes containing
EDTA. Genomic DNA was extracted by following standard
techniques (Sambrook et al., 1989). The coding regions and adjacent
splice sites of the CPOX and PPOX gene were amplified by PCR
using conditions and primers previously described in detail (Rosipal
et al., 1999; Frank et al., 2001). PCR products were subjected to
automated sequencing, using an ABI Prism 377 Genetic Analyzer
(Applied Biosystems, Foster City, CA). Sequence deviations were
detected using the programs Phred, Phrap, and Consed, as described
previously (Codon Code Corporation, Dedham, MA; Ewing and
Green, 1998; Ewing et al., 1998; Gordon et al., 1998).
Reverse transcription-PCR and quantitative real-time PCR
Total RNA was extracted from peripheral blood mononuclear cells
using the RNeasy kit (Qiagen, Venlo, the Netherlands). Comple-
mentary DNA was obtained by reverse transcription of total RNA
using the Transcriptor High Fidelity cDNA Synthesis Kit with
random hexameric primers (Roche Applied Sciences, Almere,
the Netherlands). To enable genetic analysis of the CPOX transcripts,
PCR was performed using primers encompassing exon 2 of the
CPOX gene. The resulting product was cloned in the pCR-XL-TOPO
vector (Invitrogen, Carlsbad, CA) according to the manufacturer’s
guidelines. A total of 20 clones were selected and, subsequently,
the insert was subjected to automated sequencing as described
earlier.
mRNA levels for CPOX and PPOX were measured in RNA
specimens from the patient and an age- and gender-matched healthy
donor. Therefore, total RNA was derived from whole blood samples
using PAXgene Collection Tubes and PAXgene Blood RNA
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Amounts of total RNA were measured using the
NanoDrop system (NanoDrop Technologies, Rockland, DE), and
equal RNA concentrations of each sample were used for quantitative
reverse transcription PCR analysis. TaqMan experiments were
conducted on an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems) using Assay-on-Demand gene expression
products for CPOX (Hs00164367_m1), PPOX (Hs00609392_m1)
and 18S (Hs99999901_s1). All measurements were recorded in
triplicates in separate reaction wells. The relative mRNA levels were
normalized to 18S.
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